Felon Accused in Brain Tumour Resistance to Therapy

Relentless protein expression may clarify why tumours revisit after therapy in glioblastoma patients, states study published on March 5th in the Journal of Experimental Medicine.

Current therapy for glioblastoma, the most prevalent malignant brain tumor in adults, includes targeting a protein called VEGF, which promotes the growth of blood vessels to the tumor. Unfortunately, in most glioblastoma patients treated with anti-VEGF drugs, tumors return shortly after treatment.

Showing Brain Tumour Eradication and Extended Survival: Study Published In Neuro-Oncology
Tocagen Inc. presented the company's investigational treatment for high grade glioma that wipes out brain tumours and presents a vivid survival advantage in mouse models of glioblastoma.

Through an international collaboration, Jiri Bartek, Jeremy Rich, and colleagues now show that these recurring tumors express a perpetually activated form of the VEGF receptor. This active VEGF receptor drives growth of the tumor even when VEGF is blocked. Directly inhibiting the VEGF receptor, however, killed the tumors and extended the survival of tumor-bearing mice that were resistant to VEGF blockade.

These results suggest that blocking this active VEGF receptor may represent an alternative treatment option in glioblastoma cases where VEGF targeting has failed.

Source-Eurekalert

Feasible New Pathway Can Inhibit Glioblastoma Resistance
Fatal brain cancer Glioblastoma is among the most stubbornly resistant to available therapies and patients on an average live about 15 months.

Nanoparticles Effective in Destroying Glioblastoma in Mice
Glioblastoma happens to be one of the most aggressive forms of brain cancer.

Glioblastomas can be Treated by Gamma Knife
Results from a cutting-edge research study that treated the aggressive brain tumors glioblastoma multiforme (GBM) using a novel type of imaging called MR spectroscopy